AMAG:NSD-AMAG Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.04

Change

+0.17 (+1.86)%

Market Cap

USD 0.31B

Volume

0.38M

Average Target Price

USD 9.67 (+6.93%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.69 (-0.26%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-7.73 (-1.37%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+0.16 (+0.09%)

USD31.19B N/A N/A
MRNA Moderna, Inc

-1.99 (-2.96%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-1.55 (-3.71%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

-0.41 (-0.36%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+1.89 (+0.69%)

USD24.64B N/A N/A
GMAB Genmab A/S

-1.06 (-2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.13 (+0.15%)

USD19.69B N/A N/A
INCY Incyte Corporation

-0.90 (-1.05%)

USD18.80B 47.64 35.20

ETFs Containing AMAG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.72% 34% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.72% 34% F 34% F
Trailing 12 Months  
Capital Gain -28.93% 27% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.93% 27% F 29% F
Trailing 5 Years  
Capital Gain -79.33% 28% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.33% 28% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -17.83% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.83% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.01% N/A N/A N/A N/A
Risk Adjusted Return -61.45% N/A N/A N/A N/A
Market Capitalization 0.31B 52% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 58.10 16% F 20% F
Price/Book Ratio 1.31 90% A- 66% D
Price / Cash Flow Ratio -2.43 28% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -69.13% 48% F 19% F
Return on Invested Capital -55.93% 57% F 18% F
Return on Assets -6.60% 89% B+ 30% F
Debt to Equity Ratio 96.82% 18% F 24% F
Technical Ratios  
Short Ratio 25.88 3% F 1% F
Short Percent 64.58% 0% N/A 4% F
Beta 1.12 68% D+ 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector